Trial · NCT05814159
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
NCT05814159, Phase 3, Active not recruiting, Swedish Orphan Biovitrum
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD). Trials, record NCT05814159. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05814159
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
- NCT number
- NCT05814159
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 15 participants, actual
- Lead sponsor
- Swedish Orphan Biovitrum
- Conditions
- Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
- Interventions
- Anakinra, Placebo
- First posted
- 2023-04-14
- Last updated
- 2025-03-05
Source ClinicalTrials.gov
Registered outcomes62
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | An improvement of ≥ 30% from baseline in physician global assessment of disease activity (visual analogue scale [VAS]). | Week 2 | ACR30 response with absence of fever attributable to the disease during the 7 days |
| Primary | An improvement of ≥ 30% from baseline in patient/parent global assessment of overall well-being (VAS). | Week 2 | ACR30 response with absence of fever attributable to the disease during the 7 days |
| Primary | An improvement of ≥ 30% from baseline in number of joints with active arthritis. | Week 2 | ACR30 response with absence of fever attributable to the disease during the 7 days |
| Primary | An improvement of ≥ 30% from baseline in number of joints with limitation of motion. | Week 2 | ACR30 response with absence of fever attributable to the disease during the 7 days |
| Primary | An improvement of ≥ 30% from baseline in assessment of physical function: Child health assessment questionnaire (CHAQ)/Stanford health assessment questionnaire (SHAQ). | Week 2 | ACR30 response with absence of fever attributable to the disease during the 7 days |
| Primary | An improvement of ≥ 30% from baseline in C-reactive protein (CRP) (mg/L). | Week 2 | ACR30 response with absence of fever attributable to the disease during the 7 days |
| Secondary | Change in CRP. | Week 2 | To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease. |
| Secondary | Change in ferritin. | Week 2 | To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease. |
| Secondary | Change in haemoglobin. | Week 2 | To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease. |
| Secondary | Change in platelets count. | Week 2 | To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease. |
1 to 10 of 62Source ClinicalTrials.gov
See all 62 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05814159
GET https://conductscience.org/api/trials/v1/NCT05814159/registered?page=2